Recent Updates
Recently added Catalysts
ENTA Positive Sentiment

Oral STAT6 Inhibitor EPS-3903 Demonstrates Good Preclinical In Vivo Tolerability Without Reactive Metabolites or Metabolic/Safety Liability In Vitro or In Vivo

Thursday, April 16, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: The article discusses the promising preclinical results of the oral STAT6 inhibitor EPS-3903. It highlights the compound's good tolerability in vivo, with no evidence of reactive metabolites or metabolic and safety liabilities. These findings suggest a favorable profile for EPS-3903 in future clinical development.
Price reaction · baseline $14.55 (2026-04-15 close) · hit pre-market · 5 other ENTA headline(s) in the window, move may be shared
day 0 close · peak
-3.4%

Market Sentiment Analysis

POSITIVE FACTORS

  • EPS-3903 shows good preclinical tolerability.
  • No reactive metabolites detected.
  • No metabolic or safety liabilities identified.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~63 mo
Minimal dilution risk
Lead asset
EDP-235
Phase 2 · COVID-19

Full Press Release Details

• About About Us Management Team Board of Directors Timeline
• Pipeline Overview Hepatitis C Virus Respiratory Syncytial Virus SARS-CoV-2 Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• Science Overview Publications
• Patients Overview Clinical Trials Expanded Access Policy Resources
• Careers Join Us Culture Core Values Testimonials Benefits
• Collaborations Partnering
• Investors Overview Press Releases Events & Presentations Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage Financials Quartlery Results Annual Reports SEC Filings Corporate Responsibility Overview Environmental Social Governance Investor Resources Investor FAQs RSS Feed 2026 Annual Meeting Email Alerts
• Contact Us
• About Us
• Management Team
• Board of Directors
• Timeline
• Overview
• Hepatitis C Virus
• Respiratory Syncytial Virus
• SARS-CoV-2
• Immunology KIT Inhibition STAT6 Inhibition MRGPRX2
• KIT Inhibition
• STAT6 Inhibition
• MRGPRX2
• Overview
• Publications
• Overview
• Clinical Trials
• Expanded Access Policy
• Resources
• Join Us
• Culture
• Core Values
• Testimonials
• Benefits
• Partnering
• Overview
• Press Releases
• Events & Presentations
• Stock Information Stock Quote & Chart Historic Price Lookup Investment Calculator Analyst Coverage
• Financials Quartlery Results Annual Reports SEC Filings
• Corporate Responsibility Overview Environmental Social Governance
• Investor Resources Investor FAQs RSS Feed
• 2026 Annual Meeting
• Email Alerts
• Stock Quote & Chart
• Historic Price Lookup
• Investment Calculator
• Analyst Coverage
• Quartlery Results
• Annual Reports
• SEC Filings
• Overview
• Environmental
• Social
• Governance
• Investor FAQs
• RSS Feed
• Print Page Print Page
• Email Alerts Email Alerts
• RSS Feeds RSS Feeds
• Contact IR Contact IR

Frequently Asked Questions

What is EPS-3903?

EPS-3903 is an oral STAT6 inhibitor undergoing preclinical evaluation.

What were the findings for EPS-3903?

EPS-3903 demonstrated good tolerability in vivo without reactive metabolites.

Are there any safety liabilities associated with EPS-3903?

No metabolic or safety liabilities were identified in the preclinical studies.

ShareAdd on Google
Tags: ENTA Viatris Investor Conferences Healthcare EPS-3903 STAT6 inhibitor preclinical results safety profile
Last updated: Apr 16, 2026

Biotech snapshot

Cash runway
$211M liquidity · $3M/mo burn
~63 mo
Minimal dilution risk
Lead asset
EDP-235Phase 2
COVID-19 →